CI-135 CAR-T / Beijing Boren Hospital - LARVOL DELTA

Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=7 | Recruiting | Sponsor: Hrain Biotechnology Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Beijing Boren Hospital | Trial completion date: Dec 2025 ➔ Dec 2023 | Recruiting ➔ Withdrawn | Trial primary completion date: Dec 2024 ➔ Dec 2023

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Trial withdrawal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3